VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                          

 

29th December 2013 - New research

L-DOPA PRODRUG FOR PARKINSON'S DISEASE

Movement Disorders [2013] Dec 13 [Epub ahead of print (P.A.Lewitt, F.J.Huff, R.A.Hauser, D.Chen, D.Lissin, K.Zomorodi, K.C.Cundy)  Complete abstract

XP21279 is a new L-dopa prodrug being developed by Xenoport for the treatment of Parkinson's Disease. It uses naturally occurring, high capacity nutrient transporters in the gastrointestinal tract to generate active and efficient absorption into the body.

XP21279-carbidopa sustained-release bilayer tablets were developed to provide more continuous exposure to L-dopa. Once absorbed, XP21279 is rapidly converted into L-dopa. In a clinical trial of XP21279, people with Parkinson's Disease were given either XP21279 with carbidopa, or L-dopa with carbidopa, which as Sinemet is the most common means of treating Parkinson's Disease.

The average daily off time was reduced more when using XP21279 but only by 18 minutes. There was little difference between the two in their effect on dyskinesia. However, XP21279 significantly reduced the variability of L-dopa concentration that occurs when using Sinemet (L-dopa and carbidopa). This was achieved by taking XP21279 only three times per day, instead of the four to five times a day that the L-dopa with carbidopa was taken. Therefore, overall, although L-dopa and carbidopa as Sinemet is the most common means of treating Parkinson's Disease, XP21279 was found to be more advantageous. For more news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
2006-2014  Viartis
 
2015-08-08 22:23:59
 
[email protected]